 Artist: Chaos UK: mp3 download Genre(s): Rock: Punk-Rock Discography:  1993 - 100 Percent 2 Fingers in the Air Punk Rock Year: 1993 Tracks: 20 Punk rock candy heroes Chaos UK began its recollective journey in 1979, with a wit consisting of vocaliser Simon, guitarist Andy, bassist Kaos, and drummer Potts. They finally signed with Riot City Records and released deuce 7" records in 1982. That same year, they released an eponymic LP with a slimly different card. Kaos had moved to vocals, and young members Spot and Nige took over on drums and bass, respectively. They leftfield the label before long after and disappeared until 1984's Lawless Britain, in any case known as Short Sharp Shock, which came out on Children of the Revolution Records. They as well had a young lineup at this point, at present featuring isaac Bashevis Singer Mower, drummer Chuck, guitar player Gabba, and Kaos. An interesting minor disputation would end point role from this album, as Michelle Shocked would release an album called Short Sharp Shocked with virtually the same pass over graphics, often to the band's discouragement. The menu actually lasted to the following album, 1986's Radioactive Earslaughter, which came out at the same time as a split saucer with Extreme Noise Terror. Without whatever real tenableness, they went into semi-retirement most immediately later, staying out of the euphony picture until 1989, which saw the release of Chipping Sodbury Bonfire Tapes on their have Slap Up Records. The form of address was a grasp at Shocked, wHO had an album coroneted The Texas Campfire Tapes. Mower would shortly allow behind the band, delivery Kaos indorse to vocals and delivery in Beki on bass. The Live in Japan record album was recorded in 1991 (although it came out trey long time later), just after their tour of the eastern United States they would lose Chuck and put back him with Devilman. They as comfortably added a secondment guitar player, Vic (ex-Reagan Youth). This card would tone ending the Making Half a Killing record album concisely after (the championship is a play on some other Extreme Noise Terror split disc). 1993 saw the tone ending of One Hundred Percent Two Fingers in the Air on Century Media Records. New drummer Phil Thudd and unexampled bassist J. sign-language on for King for a Day (1996), Morning After the Night Before (1996), and Heard It, Seen It, Done It (1997), merely Devilman was noneffervescent in the stripe and even played on the albums piece Beki had since left hand. Members of the dance band began to start side projects, including A.D. Rice and the Wuzzuks, just they inactive released Total Chaos in 1999 and Chaos in Japan in 2001. |
Saturday 23 August 2008
Download Chaos UK mp3
Wednesday 13 August 2008
Cancer Researchers And Oncologists Offer A Clinical Trial For Multiple Myeloma Patients
�Cancer researchers at George Mason University's Center for Applied Proteomics and Molecular Medicine ar studying the effects of experimental treatments on living tumor cells taken from multiple myeloma patients wHO are undergoing a routine diagnostic process.
The trial may resultant in the discovery of novel therapeutic targets for treatment of this incurable form of blood cancer expected to strike nearly 20,000 men and women this year.
CAPMM co-directors Lance Liotta and Emanuel Petricoin III are partnering with oncologists at Fairfax-Northern Virginia Hematology Oncology in a clinical programme for multiple myeloma patients to examine protein signal pathway activity in pathological cells and determine what type of drug interposition is required to forestall further growth of the disease.
"This is non a patient treatment trial," explains Liotta. "Instead, living cells from a biopsy are treated in culture immediately after being remote from the patient."
Trial participants will undergo a bone bone marrow biopsy, which is parting of the routine banner of concern practices for an existing or suspected multiple myeloma diagnosis. Once the berth procedure is performed, extra material not required for diagnosis is immediately preserved and taken to the CAPMM laboratories for analysis.
"Our information indicate that the protein signaling pathways that control cellular activity are different in each patient's tumor," Liotta says. "This novel trial testament test a large series of targeted inhibitors, alone and in unique combinations, which block key signaling pathways in the neoplasm cells. This is a key first base step toward true personalized therapy for multiple myeloma."
Currently, treatment of multiple myeloma is based on a one-size-fits-all approach that fails to consider the protein sign information, Petricoin adds. "Since this information underpins the growth and survival of the crab cells, we hypothesize that turning patient-specific signaling activation off will kill the tumor cells more effectively than the current intervention," he says. "In this initial study, we volition test hopeful new treatments that crataegus laevigata be candidates for Phase I or II clinical treatment research trials."
The research is funded by local philanthropist Chris Walker. "This is an exemplar of serendipity and opportunity, and that is what makes America a particular place -- where beneficial people and good ideas garner support from pluralistic sources," he says. "Cancer, in peculiar, needs some new ideas since the old approaches aren't working."
Multiple myeloma is a treatable progressive disease that attacks the plasma cell, a vital part of the immune system that produces antibodies to fight infection and disease. One of the leading causes of malignant neoplastic disease death among African Americans, it is the second base most rife blood genus Cancer in the United States and strikes more ofttimes in work force than women.
Patients interested in active in this multiple myeloma trial mustiness be referred by their physicians for an eligibility screening. For additional information contact Denise Campbell, Fairfax-Northern Virginia Hematology Oncology, at 703-280-5390.
George Mason University
More info
The trial may resultant in the discovery of novel therapeutic targets for treatment of this incurable form of blood cancer expected to strike nearly 20,000 men and women this year.
CAPMM co-directors Lance Liotta and Emanuel Petricoin III are partnering with oncologists at Fairfax-Northern Virginia Hematology Oncology in a clinical programme for multiple myeloma patients to examine protein signal pathway activity in pathological cells and determine what type of drug interposition is required to forestall further growth of the disease.
"This is non a patient treatment trial," explains Liotta. "Instead, living cells from a biopsy are treated in culture immediately after being remote from the patient."
Trial participants will undergo a bone bone marrow biopsy, which is parting of the routine banner of concern practices for an existing or suspected multiple myeloma diagnosis. Once the berth procedure is performed, extra material not required for diagnosis is immediately preserved and taken to the CAPMM laboratories for analysis.
"Our information indicate that the protein signaling pathways that control cellular activity are different in each patient's tumor," Liotta says. "This novel trial testament test a large series of targeted inhibitors, alone and in unique combinations, which block key signaling pathways in the neoplasm cells. This is a key first base step toward true personalized therapy for multiple myeloma."
Currently, treatment of multiple myeloma is based on a one-size-fits-all approach that fails to consider the protein sign information, Petricoin adds. "Since this information underpins the growth and survival of the crab cells, we hypothesize that turning patient-specific signaling activation off will kill the tumor cells more effectively than the current intervention," he says. "In this initial study, we volition test hopeful new treatments that crataegus laevigata be candidates for Phase I or II clinical treatment research trials."
The research is funded by local philanthropist Chris Walker. "This is an exemplar of serendipity and opportunity, and that is what makes America a particular place -- where beneficial people and good ideas garner support from pluralistic sources," he says. "Cancer, in peculiar, needs some new ideas since the old approaches aren't working."
Multiple myeloma is a treatable progressive disease that attacks the plasma cell, a vital part of the immune system that produces antibodies to fight infection and disease. One of the leading causes of malignant neoplastic disease death among African Americans, it is the second base most rife blood genus Cancer in the United States and strikes more ofttimes in work force than women.
Patients interested in active in this multiple myeloma trial mustiness be referred by their physicians for an eligibility screening. For additional information contact Denise Campbell, Fairfax-Northern Virginia Hematology Oncology, at 703-280-5390.
George Mason University
More info
Wednesday 6 August 2008
Subscribe to:
Posts (Atom)